胸膜间皮瘤的既定和新的治疗路线图:土耳其合作小组的意见。

IF 2.5 4区 医学 Q3 ONCOLOGY Current Problems in Cancer Pub Date : 2023-09-27 DOI:10.1016/j.currproblcancer.2023.101017
Muhammet Ali Kaplan , Mehmet Ali Nahit Şendur , Ayten Kayı Cangır , Pınar Fırat , Erdem Göker , Saadettin Kılıçkap , Başak Oyan , Ayşim Büge Öz , Feyyaz Özdemir , Gökhan Özyiğit
{"title":"胸膜间皮瘤的既定和新的治疗路线图:土耳其合作小组的意见。","authors":"Muhammet Ali Kaplan ,&nbsp;Mehmet Ali Nahit Şendur ,&nbsp;Ayten Kayı Cangır ,&nbsp;Pınar Fırat ,&nbsp;Erdem Göker ,&nbsp;Saadettin Kılıçkap ,&nbsp;Başak Oyan ,&nbsp;Ayşim Büge Öz ,&nbsp;Feyyaz Özdemir ,&nbsp;Gökhan Özyiğit","doi":"10.1016/j.currproblcancer.2023.101017","DOIUrl":null,"url":null,"abstract":"<div><p>Pleural mesothelioma (PM) is a cancer of the pleural surface, which is aggressive and may be rapidly fatal. PM is a rare cancer worldwide, but is a relatively common disease in Turkey. Asbestos exposure is the main risk factor and the most common underlying cause of the disease. There have been significant improvements in diagnoses and treatments of many malignancies; however, there are still therapeutic challenges in PM. In this review, we aimed to increase the awareness of health care professionals, oncologists, and pulmonologists by underlining the unmet needs of patients with PM and by emphasizing the need for a multidisciplinary treatment and management of PM. After reviewing the general information about PM, we further discuss the treatment options for patients with PM using immunotherapy and offer evidence for improvements in the clinical outcomes of these patients because of these newer treatment modalities.</p></div>","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2023-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0147027223000703/pdfft?md5=e62c7ae8a65347014efe3625160d7c78&pid=1-s2.0-S0147027223000703-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Established and new treatment roadmaps for pleural mesothelioma: opinions of the Turkish Collaborative Group\",\"authors\":\"Muhammet Ali Kaplan ,&nbsp;Mehmet Ali Nahit Şendur ,&nbsp;Ayten Kayı Cangır ,&nbsp;Pınar Fırat ,&nbsp;Erdem Göker ,&nbsp;Saadettin Kılıçkap ,&nbsp;Başak Oyan ,&nbsp;Ayşim Büge Öz ,&nbsp;Feyyaz Özdemir ,&nbsp;Gökhan Özyiğit\",\"doi\":\"10.1016/j.currproblcancer.2023.101017\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Pleural mesothelioma (PM) is a cancer of the pleural surface, which is aggressive and may be rapidly fatal. PM is a rare cancer worldwide, but is a relatively common disease in Turkey. Asbestos exposure is the main risk factor and the most common underlying cause of the disease. There have been significant improvements in diagnoses and treatments of many malignancies; however, there are still therapeutic challenges in PM. In this review, we aimed to increase the awareness of health care professionals, oncologists, and pulmonologists by underlining the unmet needs of patients with PM and by emphasizing the need for a multidisciplinary treatment and management of PM. After reviewing the general information about PM, we further discuss the treatment options for patients with PM using immunotherapy and offer evidence for improvements in the clinical outcomes of these patients because of these newer treatment modalities.</p></div>\",\"PeriodicalId\":55193,\"journal\":{\"name\":\"Current Problems in Cancer\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2023-09-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S0147027223000703/pdfft?md5=e62c7ae8a65347014efe3625160d7c78&pid=1-s2.0-S0147027223000703-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Problems in Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0147027223000703\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Problems in Cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0147027223000703","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

胸膜间皮瘤(PM)是一种胸膜表面的癌症,具有侵袭性,可能迅速致命。PM是全球罕见的癌症,但在土耳其是一种相对常见的疾病。石棉暴露是该疾病的主要危险因素和最常见的潜在原因。许多恶性肿瘤的诊断和治疗都有了显著的改进;然而,PM仍然存在治疗挑战。在这篇综述中,我们旨在通过强调PM患者未满足的需求,并强调对PM进行多学科治疗和管理的必要性,提高卫生保健专业人员、肿瘤学家和肺科医生的认识。在回顾了有关PM的一般信息后,我们进一步讨论了使用免疫疗法治疗PM患者的选择,并为这些新的治疗方式改善这些患者的临床结果提供了证据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Established and new treatment roadmaps for pleural mesothelioma: opinions of the Turkish Collaborative Group

Pleural mesothelioma (PM) is a cancer of the pleural surface, which is aggressive and may be rapidly fatal. PM is a rare cancer worldwide, but is a relatively common disease in Turkey. Asbestos exposure is the main risk factor and the most common underlying cause of the disease. There have been significant improvements in diagnoses and treatments of many malignancies; however, there are still therapeutic challenges in PM. In this review, we aimed to increase the awareness of health care professionals, oncologists, and pulmonologists by underlining the unmet needs of patients with PM and by emphasizing the need for a multidisciplinary treatment and management of PM. After reviewing the general information about PM, we further discuss the treatment options for patients with PM using immunotherapy and offer evidence for improvements in the clinical outcomes of these patients because of these newer treatment modalities.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Current Problems in Cancer
Current Problems in Cancer 医学-肿瘤学
CiteScore
5.10
自引率
0.00%
发文量
71
审稿时长
15 days
期刊介绍: Current Problems in Cancer seeks to promote and disseminate innovative, transformative, and impactful data on patient-oriented cancer research and clinical care. Specifically, the journal''s scope is focused on reporting the results of well-designed cancer studies that influence/alter practice or identify new directions in clinical cancer research. These studies can include novel therapeutic approaches, new strategies for early diagnosis, cancer clinical trials, and supportive care, among others. Papers that focus solely on laboratory-based or basic science research are discouraged. The journal''s format also allows, on occasion, for a multi-faceted overview of a single topic via a curated selection of review articles, while also offering articles that present dynamic material that influences the oncology field.
期刊最新文献
Artificial intelligence-based pathological application to predict regional lymph node metastasis in Papillary Thyroid Cancer Four versus six cycles of platinum-based chemotherapy for advanced Urothelial carcinoma in the era of immune checkpoint inhibitors: A retrospective cohort study (FOCUS, KCSG-GU23-08) Metaplastic breast cancer: Experience with ifosfamide based chemotherapy Table of Contents Title Page
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1